Teva Pharmaceutical Industries Limited

Equities

TEVA

US8816242098

Pharmaceuticals

Market Closed - Nyse 04:00:03 2024-06-21 pm EDT 5-day change 1st Jan Change
16.96 USD -0.59% Intraday chart for Teva Pharmaceutical Industries Limited -1.17% +62.45%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Teva Pharmaceutical Industries 'Well-Positioned' for Further Growth, UBS Says MT
Global markets live: Tesco, Adobe, Tyson Foods, GameStop, Teva... Our Logo
Teva Pharmaceutical Sues Corcept Therapeutics Alleging Market Monopolization for Cushing's Syndrome Drug Korlym MT
Transcript : Teva Pharmaceutical Industries Limited Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 08:00 AM
Barclays Adjusts Price Target on Teva Pharmaceutical Industries to $21 From $20, Maintains Overweight Rating MT
Teva Pharmaceutical Gains FDA Approval for Daily Huntington's Disease Pill MT
Teva Pharmaceutical Industries Limited Announces AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets Now U.S. FDA Approved as a One Pill, Once-Daily Treatment Option for Clinically Therapeutic Doses (24?48 mg/day) CI
Teva Pharmaceutical Industries Limited and Alvotech Announce SIMLANDI® Injection Now Available in the U.S CI
Teva Pharmaceutical Industries Insider Sold Shares Worth $470,794, According to a Recent SEC Filing MT
Teva Pharmaceutical Industries Insider Sold Shares Worth $254,807, According to a Recent SEC Filing MT
Teva Pharmaceutical Industries Limited Announces Management Changes, Effective June 3, 2024 CI
Transcript : Teva Pharmaceutical Industries Limited Presents at Bank of America Health Care Conference 2024, May-14-2024 08:40 AM
Piper Sandler Adjusts Price Target on Teva Pharmaceutical Industries to $20 From $19, Maintains Overweight Rating MT
Sector Update: Health Care Stocks Slipping Wednesday Afternoon MT
Teva Pharmaceutical Shares Rise After Reporting Higher Q1 Earnings, Revenue; 2024 Guidance Reaffirmed MT
Sector Update: Health Care Stocks Lean Lower Pre-Bell Wednesday MT
Sector Update: Health Care MT
Teva Pharmaceutical Industries Q1 Non-GAAP Earnings, Revenue Rise; 2024 Guidance Reaffirmed MT
Earnings Flash (TEVA) TEVA PHARMACEUTICAL INDUSTRIES LIMITED Posts Q1 Revenue $3.82B MT
Earnings Flash (TEVA) TEVA PHARMACEUTICAL INDUSTRIES LIMITED Posts Q1 EPS $0.48 MT
Transcript : Teva Pharmaceutical Industries Limited, Q1 2024 Earnings Call, May 08, 2024
Teva Pharm Q1 profit falls short of estimates, revenue gains RE
Teva Pharmaceutical Industries Limited Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Teva Pharmaceutical Industries Limited Reports Impairment of Long-Lived Assets for the Three Months Ended March 31, 2024 CI
Teva Pharmaceutical Industries Limited Reaffirms Earnings Guidance for the Full Year 2024 CI
Chart Teva Pharmaceutical Industries Limited
More charts
Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
16.96 USD
Average target price
18.34 USD
Spread / Average Target
+8.11%
Consensus
  1. Stock Market
  2. Equities
  3. TEVA Stock
  4. News Teva Pharmaceutical Industries Limited
  5. Sector Update: Health Care Stocks Lean Lower Pre-Bell Wednesday